Stock / Equity
NASDAQ
CUSIP 67066G104
15-min delayed
DEMO
TLSI NVIDIA Corporation
Biotechnology ·
$272M mkt cap ·
held by 0 superinvestors
$142.18
▲ 5.74
(+4.21%) today
Overview
Financials
Ownership
Forecasts
Signals
Price · Candlestick + Volume
1D
1W
1M
3M
1Y
5Y
O 137.42
H 143.51
L 136.91
C 142.18
O
H
L
C
VOL
Open
137.42
High
143.51
day
Low
136.91
day
Volume
284.6M
Avg Vol
212.4M
Mkt Cap
$272M
P/E
—
52W H/L
152.84 / 86.62
Latest news
real-time
0 items
No news available right now.
Retail sentiment
r/wallstreetbets · 24h
TLSI is not currently trending on r/WallStreetBets — no mentions in the last 24 hours.
About
company
CEO
—
Employees
—
HQ
US
IPO
Dec 18 2020
Website
trisaluslifesci.com
Revenue (FY 2025)
$45M
▲ +53% YoY
Net Income (FY 2025)
$39M
▼ -31% YoY
FCF (FY 2025)
$19M
▲ +54% YoY
Gross Margin
84.6%
▼ -1.5pp
Income Statement
Balance Sheet
Cash Flow
Key Ratios
Annual
Quarterly
Revenue & Profitability
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Revenue | $45.2M | $29.4M | — | $12.4M | — |
| Cost of Revenue | $7.0M | $4.1M | — | $2.3M | — |
| Gross Profit | $38.2M | $25.3M | — | $10.1M | — |
| R&D Expenses | $15.0M | $17.7M | — | $21.4M | — |
| Operating Income | $-26.9M | $-36.2M | — | $-36.4M | $-3.0M |
| Interest Expense | — | — | $16.0K | $1.0K | — |
| Pre-Tax Income | $-39.2M | $-30.0M | — | $-47.2M | $4.8M |
| Income Tax | $7.0K | $6.0K | — | $9.0K | $0 |
| Net Income | $-39.2M | $-30.0M | — | $-47.2M | $4.8M |
| EPS (Basic) | $-1.84 | $-1.31 | — | $-161.55 | — |
| EPS (Diluted) | $-1.84 | $-1.31 | — | $-161.55 | — |
| 09/2025 | 06/2025 | 03/2025 | 09/2024 | 06/2024 | |
|---|---|---|---|---|---|
| Revenue | $11.6M | $11.2M | $9.2M | $7.3M | $7.4M |
| Cost of Revenue | $1.9M | $1.8M | $1.5M | $1.0M | $912.0K |
| Gross Profit | $9.7M | $9.4M | $7.7M | $6.3M | $6.5M |
| R&D Expenses | $5.2M | $3.9M | $3.3M | $4.2M | $4.7M |
| Operating Income | $-9.0M | $-7.3M | $-7.3M | $-8.7M | $-8.2M |
| Interest Expense | — | — | — | — | $877.0K |
| Pre-Tax Income | $-10.8M | $-8.3M | $-10.4M | $-2.4M | $-4.3M |
| Income Tax | $5.0K | $-3.0K | $5.0K | $-3.0K | $7.0K |
| Net Income | $-10.8M | $-8.3M | $-10.4M | $-2.4M | $-4.3M |
| EPS (Basic) | $-0.96 | $-0.27 | $-0.39 | $-0.12 | $-0.21 |
| EPS (Diluted) | $-0.96 | $-0.27 | $-0.39 | $-0.12 | $-0.21 |
Asset Composition
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $20.4M | $8.5M | $12.1M | $9.4M | $200.9K |
| Accounts Receivable | $6.6M | $5.1M | — | $1.6M | — |
| Inventory | $3.1M | $4.0M | — | $1.5M | — |
| Total Current Assets | $32.2M | $20.7M | — | $17.2M | $525.9K |
| Intangible Assets | — | — | — | $802.0K | — |
| Total Assets | $35.3M | $24.0M | — | $22.0M | $250.5M |
| Accounts Payable | — | — | — | — | $1.1M |
| Total Current Liabilities | $11.5M | $10.2M | — | $32.4M | $1.6M |
| Long-Term Debt | $33.0M | $22.1M | — | — | — |
| Total Liabilities | $69.2M | $49.9M | — | $34.3M | $17.3M |
| Total Equity | $-33.9M | $-25.9M | $-27.1M | — | $-129.6M |
| 09/2025 | 06/2025 | 03/2025 | 09/2024 | 06/2024 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $22.7M | $26.5M | $13.0M | $11.3M | $16.5M |
| Accounts Receivable | $5.0M | $5.6M | $5.5M | $4.9M | $4.7M |
| Inventory | $3.3M | $3.8M | $4.2M | $4.0M | $3.4M |
| Total Current Assets | $33.3M | $38.1M | $25.1M | $23.8M | $27.9M |
| PP&E (Net) | — | — | — | $1.8M | $1.8M |
| Intangible Assets | — | — | — | — | $1.1M |
| Total Assets | $36.5M | $41.3M | $28.6M | $27.5M | $32.4M |
| Total Current Liabilities | $10.9M | $9.3M | $11.8M | $9.9M | $12.0M |
| Long-Term Debt | $32.8M | $32.3M | $31.7M | $21.7M | $21.3M |
| Total Liabilities | $63.2M | $60.7M | $63.0M | $47.9M | $56.6M |
| Total Equity | $-26.7M | $-19.4M | $-34.4M | $-20.4M | $-25.3M |
Cash Flow Analysis
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Operating Cash Flow | $-18.0M | $-40.8M | — | $-32.3M | $-1.7M |
| Capital Expenditures | $918.0K | $345.0K | — | $655.0K | — |
| Depreciation & Amortization | $626.0K | $744.0K | — | $398.0K | — |
| Stock-Based Compensation | $9.1M | $5.4M | — | $368.0K | — |
| Investing Cash Flow | $-838.0K | $-345.0K | — | $-1.8M | $60.0K |
| Share Repurchases | — | — | — | $232.4M | — |
| Financing Cash Flow | $30.8M | $37.9M | — | $13.5M | $544.0K |
| 09/2025 | 06/2025 | 03/2025 | 09/2024 | 06/2024 | |
|---|---|---|---|---|---|
| Operating Cash Flow | — | — | $-4.5M | — | — |
| Capital Expenditures | — | — | $754.0K | — | — |
| Depreciation & Amortization | — | — | $172.0K | — | — |
| Stock-Based Compensation | — | — | $1.6M | — | — |
| Investing Cash Flow | — | — | $-714.0K | — | — |
| Financing Cash Flow | — | — | $9.7M | — | — |
Margin & Return Trends
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Gross Margin | 84.6% | 86.1% | — | 81.8% | — |
| Operating Margin | -59.7% | -122.9% | — | -293.9% | — |
| Net Margin | -86.9% | -102.1% | — | -380.6% | — |
| ROE | 115.8% | 116.0% | — | — | -3.7% |
| ROA | -111.0% | -125.3% | — | -214.5% | 1.9% |
| Current Ratio | 2.80x | 2.02x | — | 0.53x | 0.33x |
| Quick Ratio | 2.54x | 1.63x | — | 0.49x | 0.33x |
| Debt / Equity | -2.04x | -1.93x | — | — | -0.13x |
| Interest Coverage | — | — | — | -36439.00x | — |
| Revenue Growth YoY | 53.4% | — | — | — | — |
| Free Cash Flow | -18930000.00x | -41188000.00x | — | -32968000.00x | -1738114.00x |
| FCF Margin | -41.9% | -139.9% | — | -265.9% | — |
| Asset Turnover | 1.28x | 1.23x | — | 0.56x | — |
| 09/2025 | 06/2025 | 03/2025 | 09/2024 | 06/2024 | |
|---|---|---|---|---|---|
| Gross Margin | 83.5% | 83.9% | 83.7% | 86.3% | 87.6% |
| Operating Margin | -77.9% | -65.4% | -79.9% | -118.9% | -111.0% |
| Net Margin | -93.5% | -73.9% | -113.2% | -32.6% | -58.8% |
| ROE | 40.5% | 42.7% | 30.2% | 11.7% | 17.1% |
| ROA | -29.6% | -20.1% | -36.2% | -8.7% | -13.4% |
| Current Ratio | 3.05x | 4.08x | 2.14x | 2.40x | 2.33x |
| Quick Ratio | 2.75x | 3.68x | 1.78x | 2.00x | 2.04x |
| Debt / Equity | -2.36x | -3.13x | -1.83x | -2.34x | -2.24x |
| Interest Coverage | — | — | — | — | -9.32x |
| Revenue Growth YoY | 3.1% | 22.3% | 24.7% | -0.2% | — |
| Free Cash Flow | — | — | -5253000.00x | — | — |
| FCF Margin | — | — | -57.3% | — | — |
| Asset Turnover | 0.32x | 0.27x | 0.32x | 0.27x | 0.23x |
Funds
Congress
Insiders
SEC Filings
0 institutional holders · combined —
| # | Holder | Manager | Shares | Value | Port % of fund | QoQ Δ |
|---|
Recent trades
newest first
| Member | Chamber | Action | Trade size | Filed | Disclosure delay |
|---|
Insider purchase insights
based on 15 open market purchases · 2024-09-10 – 2026-02-23
Buy activity
5
in last 12mo
● Quiet
vs 10.3/yr avg
Insider buying zone
$4.68
avg price
Range: $3.97 – $5.65
Purchase win rate
—
Computing…
After insider buys (90d)
—
Computing forward returns…
Insider trading
27 Form 4 filings for TLSI
Stansky Michael P
Dir
1 buy · $1.5M
Last: Feb 23 2026
Holds 986,830
Avg $4.10
Szela Mary T
CEO, Pres
5 buys · $327K
1 sell · $79K
Last: Mar 11 2026
Holds 752,987
Avg $4.68
Frankenius Equity Ab
10%
1 buy · $250K
Last: Dec 17 2024
Holds 6,230,748
Avg $3.97
Young James Emmett
CFO
2 buys · $164K
Last: Feb 05 2025
Holds 51,726
Avg $5.45
Murphy Sean
Chief Manuf, Strategy, Bus Dev
1 buy · $157K
Last: Jan 27 2025
Holds 618,555
Avg $5.24
Valle William
Dir
1 buy · $125K
Last: Feb 23 2026
Holds 30,487
Avg $4.10
Desai Arjun Jj
Dir
1 sell · $111K
Last: Dec 10 2024
Holds 247,127
Avg $3.69
Wahlstrom Mats
Dir, 10%
2 buys · $70K
Last: Nov 22 2024
Holds 2,640,014
Avg $4.44
Stevens Jennifer
Chief Regulatory Officer
2 sells · $60K
Last: Mar 11 2026
Holds 124,110
Avg $4.87
Marshak Richard
Chief Commercial Officer
2 sells · $48K
Last: Mar 11 2026
Holds 110,397
Avg $4.81
Gordon Gary B.
Dir
1 buy · $40K
Last: Feb 23 2026
Holds 9,756
Avg $4.10
Cox Bryan F.
CHIEF OF RESEARCH
3 sells · $39K
Last: Mar 11 2026
Holds 163,415
Avg $4.74
Devlin Jodi
Chief of Clinical Operations
2 sells · $38K
Last: Mar 11 2026
Holds 97,364
Avg $4.75
Patience David
CFO
1 buy · $15K
Last: Feb 23 2026
Holds 268,657
Avg $4.10
Martin George Kelly
Dir
1 sell · $50
Last: Aug 28 2024
Holds 247,176
Avg $5.56
Q1 2026 10 trades · $1.9M 5 buys 5 sells
| Insider | Title | Trade date | Type | Price | Qty | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|
| Devlin Jodi | Chief of Clinical Operations | Mar 11 2026 | Sale | $4.11 | -3,207 | -$13,171 | 97,364 (-3%) | ↗ |
| Cox Bryan F. | CHIEF OF RESEARCH | Mar 11 2026 | Sale | $4.11 | -3,184 | -$13,085 | 163,415 (-2%) | ↗ |
| Marshak Richard | Chief Commercial Officer | Mar 11 2026 | Sale | $4.11 | -3,457 | -$14,210 | 110,397 (-3%) | ↗ |
| Stevens Jennifer | Chief Regulatory Officer | Mar 11 2026 | Sale | $4.11 | -3,530 | -$14,509 | 124,110 (-3%) | ↗ |
| Szela Mary T | CEO, Pres | Mar 11 2026 | Sale | $3.91 | -20,302 | -$79,383 | 752,987 (-3%) | ↗ |
| Patience David | CFO | Feb 23 2026 | Purchase | $4.10 | +3,657 | +$14,994 | 268,657 (+1%) | ↗ |
| Gordon Gary B. | Dir | Feb 23 2026 | Purchase | $4.10 | +9,756 | +$40,000 | 9,756 (New) | ↗ |
| Valle William | Dir | Feb 23 2026 | Purchase | $4.10 | +30,487 | +$124,997 | 30,487 (New) | ↗ |
| Szela Mary T | CEO, Pres | Feb 23 2026 | Purchase | $4.10 | +30,487 | +$124,997 | 773,289 (+4%) | ↗ |
| Stansky Michael P | Dir | Feb 23 2026 | Purchase | $4.10 | +361,098 | +$1,480,502 | 986,830 (+58%) | ↗ |
Q2 2025 4 trades · $129K 4 sells
| Insider | Title | Trade date | Type | Price | Qty | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|
| Cox Bryan F. | CHIEF OF RESEARCH | May 19 2025 | Sale | $5.18 | -4,764 | -$24,678 | 119,415 (-4%) | ↗ |
| Devlin Jodi | Chief of Clinical Operations | May 19 2025 | Sale | $5.18 | -4,764 | -$24,678 | 52,764 (-8%) | ↗ |
| Marshak Richard | Chief Commercial Officer | May 19 2025 | Sale | $5.18 | -6,597 | -$34,172 | 69,101 (-9%) | ↗ |
| Stevens Jennifer | Chief Regulatory Officer | May 19 2025 | Sale | $5.18 | -8,704 | -$45,087 | 77,640 (-10%) | ↗ |
Q1 2025 5 trades · $423K 5 buys
| Insider | Title | Trade date | Type | Price | Qty | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|
| Young James Emmett | CFO | Feb 05 2025 | Purchase | $5.65 | +6,000 | +$33,900 | 51,726 (+13%) | ↗ |
| Szela Mary T | CEO, Pres | Jan 29 2025 | Purchase | $5.15 | +10,040 | +$51,754 | 444,259 (+2%) | ↗ |
| Szela Mary T | CEO, Pres | Jan 27 2025 | Purchase | $5.27 | +9,542 | +$50,303 | 434,219 (+2%) | ↗ |
| Murphy Sean | Chief Manuf, Strategy, Bus Dev | Jan 27 2025 | Purchase | $5.24 | +30,000 | +$157,200 | 618,555 (+5%) | ↗ |
| Young James Emmett | CFO | Jan 27 2025 | Purchase | $5.40 | +24,000 | +$129,600 | 45,726 (+110%) | ↗ |
Q4 2024 5 trades · $432K 3 buys 2 sells
| Insider | Title | Trade date | Type | Price | Qty | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|
| Cox Bryan F. | Chief Scientific, Manufact. | Oct 05 2024 | Sale | $4.44 | -314 | -$1,394 | 86,382 (0%) | ↗ |
| Frankenius Equity Ab | 10% | Dec 17 2024 | Purchase | $3.97 | +62,972 | +$249,999 | 6,230,748 (+1%) | ↗ |
| Desai Arjun Jj | Dir | Dec 10 2024 | Sale | $3.69 | -30,000 | -$110,700 | 247,127 (-11%) | ↗ |
| Wahlstrom Mats | Dir, 10% | Nov 22 2024 | Purchase | $4.55 | +5,000 | +$22,750 | 2,640,014 (0%) | ↗ |
| Wahlstrom Mats | Dir, 10% | Nov 20 2024 | Purchase | $4.39 | +10,727 | +$47,057 | 2,635,014 (0%) | ↗ |
Q3 2024 3 trades · $100K 2 buys 1 sell
| Insider | Title | Trade date | Type | Price | Qty | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|
| Szela Mary T | CEO, Pres | Sep 12 2024 | Purchase | $5.09 | +14,815 | +$75,359 | 384,677 (+4%) | ↗ |
| Szela Mary T | CEO, Pres | Sep 10 2024 | Purchase | $4.97 | +5,000 | +$24,850 | 369,862 (+1%) | ↗ |
| Martin George Kelly | Dir | Aug 28 2024 | Sale | $5.50 | -9 | -$50 | 247,176 (0%) | ↗ |
EDGAR filings
50 recent · TLSI
| Form | Filed | Period | Description | Link |
|---|---|---|---|---|
| 8-K | Apr 29 2026 | 2026-04-24 | 8-K | ↗ |
| 4 | Apr 20 2026 | 2025-07-31 | FORM 4 | ↗ |
| 8-K | Apr 07 2026 | 2026-04-01 | 8-K | ↗ |
| 4 | Apr 01 2026 | 2025-07-31 | FORM 4 | ↗ |
| ARS | Mar 31 2026 | 2025-12-31 | ARS | ↗ |
| DEFA14A | Mar 31 2026 | — | DEFA14A | ↗ |
| DEF 14A | Mar 31 2026 | 2025-12-31 | DEF 14A | ↗ |
| 4 | Mar 20 2026 | 2026-03-11 | FORM 4 | ↗ |
| 4 | Mar 20 2026 | 2026-03-11 | FORM 4 | ↗ |
| 4 | Mar 20 2026 | 2026-03-11 | FORM 4 | ↗ |
| 4 | Mar 20 2026 | 2026-03-11 | FORM 4 | ↗ |
| 4 | Mar 20 2026 | 2026-03-11 | FORM 4 | ↗ |
| S-8 | Mar 10 2026 | — | S-8 | ↗ |
| 10-K | Mar 05 2026 | 2025-12-31 | 10-K | ↗ |
| 8-K | Mar 05 2026 | 2026-03-05 | 8-K | ↗ |
| 424B5 | Feb 26 2026 | — | 424B5 | ↗ |
| 4 | Feb 23 2026 | 2026-02-23 | FORM 4 | ↗ |
| 4 | Feb 23 2026 | 2026-02-23 | FORM 4 | ↗ |
| 4 | Feb 23 2026 | 2026-02-23 | FORM 4 | ↗ |
| 4 | Feb 23 2026 | 2026-02-23 | FORM 4 | ↗ |
| 4 | Feb 23 2026 | 2026-02-23 | FORM 4 | ↗ |
| 424B5 | Feb 20 2026 | — | 424B5 | ↗ |
| 8-K | Feb 20 2026 | 2026-02-19 | 8-K | ↗ |
| 424B5 | Feb 19 2026 | — | 424B5 | ↗ |
| 4 | Feb 11 2026 | 2026-02-04 | FORM 4 | ↗ |
| 3 | Feb 11 2026 | 2026-02-04 | FORM 3 | ↗ |
| 8-K | Feb 09 2026 | 2026-02-03 | 8-K | ↗ |
| 8-K | Jan 12 2026 | 2026-01-12 | 8-K | ↗ |
| EFFECT | Dec 04 2025 | — | ↗ | |
| CORRESP | Dec 02 2025 | — | ↗ | |
| 4 | Nov 25 2025 | 2025-11-24 | FORM 4 | ↗ |
| 4 | Nov 25 2025 | 2025-11-24 | FORM 4 | ↗ |
| 4 | Nov 25 2025 | 2024-02-13 | FORM 4 | ↗ |
| 4 | Nov 25 2025 | 2025-11-24 | FORM 4 | ↗ |
| 4 | Nov 25 2025 | 2025-11-24 | FORM 4 | ↗ |
| 4 | Nov 25 2025 | 2025-11-24 | FORM 4 | ↗ |
| SCHEDULE 13G/A | Nov 14 2025 | — | ↗ | |
| S-3 | Nov 13 2025 | — | S-3 | ↗ |
| 10-Q | Nov 13 2025 | 2025-09-30 | 10-Q | ↗ |
| 8-K | Nov 13 2025 | 2025-11-13 | 8-K | ↗ |
| SCHEDULE 13G | Nov 03 2025 | — | ↗ | |
| 8-K | Oct 01 2025 | 2025-09-30 | 8-K | ↗ |
| 4 | Aug 29 2025 | 2025-08-28 | FORM 4 | ↗ |
| 8-K | Aug 29 2025 | 2025-08-25 | 8-K | ↗ |
| SCHEDULE 13G | Aug 18 2025 | — | ↗ | |
| 4 | Aug 15 2025 | 2025-08-14 | FORM 4 | ↗ |
| SCHEDULE 13G | Aug 14 2025 | — | ↗ | |
| 10-Q | Aug 12 2025 | 2025-06-30 | 10-Q | ↗ |
| 8-K | Aug 12 2025 | 2025-08-12 | 8-K | ↗ |
| SCHEDULE 13D/A | Aug 04 2025 | — | ↗ |
Analysts
Earnings
Estimates
Analyst consensus
52 analysts
BUY
52 firms covering · buy consensus
Price target distribution
12-month forward
Low
$80Avg
$150High
$220$142.18 NOW
$80
$115
$150
$185
$220
No earnings history available for this ticker.
No forward analyst estimates available for this ticker.
Sentiment
Short Interest
Paperpanda composite signal
NEUTRAL
Score +2
of ±100 · 1 of 8 signals positive
Signal balance
STRONG SELL
NEUTRAL
STRONG BUY
Individual signals
weighted aggregate
| Signal | Detail | Weight | Score | Verdict |
|---|---|---|---|---|
| Insider activity | 12 sells · 15 buys · 15 insiders | high |
|
|
| Congressional flow | No congressional trades | medium |
|
|
| 13F adds vs. cuts | 0 institutional holders | high |
|
|
| Analyst revisions | No analyst coverage | high |
|
|
| Retail sentiment | Not trending on r/WallStreetBets | low |
|
|
| Price momentum | Not enough price history | medium |
|
|
| Valuation | P/E unavailable | medium |
|
|
| Short interest | Short interest unavailable | low |
|
Sentiment overview
multiple sources
CNN Fear & Greed
66.9
Search interest
Google Trends · TLSI
Intent keywords
TLSI stockTLSI newsTLSI earnings
Product keywords
TLSI productsTLSI services
Comparison keywords
TLSI vs competitorTLSI review
Search interest data temporarily unavailable. Keywords above are ready for tracking.
No short interest data available for this ticker.